Last reviewed · How we verify
ABX464 Single dose
ABX464 is a small molecule that modulates the RNA splicing process to inhibit HIV replication.
ABX464 is a small molecule that modulates the RNA splicing process to inhibit HIV replication. Used for HIV infection.
At a glance
| Generic name | ABX464 Single dose |
|---|---|
| Sponsor | Abivax S.A. |
| Drug class | RNA splicing modulator |
| Target | RNA splicing process |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
ABX464 targets a novel mechanism involving the modulation of RNA splicing, which is essential for the production of viral proteins in HIV-infected cells, thereby reducing viral load.
Approved indications
- HIV infection
Common side effects
Key clinical trials
- ABX464 First in Man Study (PHASE1)
- Safety and Pharmacokinetics Study in Healthy Japanese Volunteers (PHASE1)
- Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 (PHASE1)
- Food Effect on Pharmacokinetic Parameters of ABX464 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABX464 Single dose CI brief — competitive landscape report
- ABX464 Single dose updates RSS · CI watch RSS
- Abivax S.A. portfolio CI